(firstQuint)Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency.

 PROTOCOL OUTLINE: This is a randomized, double-blind study.

 Patients are stratified by age.

 Patients are randomly assigned to androgen replacement therapy with daily dehydroepiandrosterone (DHEA) or placebo for 6 months.

 All patients may receive 6 additional months of DHEA following randomized therapy.

 Women on hormonal replacement therapy may receive concurrent conjugated estrogens or oral medroxyprogesterone.

.

 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency@highlight

OBJECTIVES: I.

 Determine the efficacy of dehydroepiandrosterone (DHEA), an androgen replacement hormone, for patients with primary adrenal insufficiency (Addison's disease).

